Investigating the Survival Benefit of Combining Radiotherapy for Surgery Treated Locally Advanced Esophageal Squamous Cell Carcinoma Patients Aged 65 and Older
- 175 Downloads
To evaluate the survival benefit of combining radiotherapy with surgery in locally advanced esophageal squamous cell carcinoma (ESCC) patients aged over 65.
Using the SEER database, we selected patients age ≥ 65 years that were diagnosed as locally advanced ESCC during 2004–2013. Cancer-specific survival (CSS) was examined using the Kaplan–Meier analysis and compared by the log-rank test. Univariable and multivariable Cox proportional hazard models were established to identify possible prognostic factors.
A total of 972 cases were included in the study. For surgical patients aged 65–79 years, 74 patients (32.9%) were treated by surgery alone and 122 patients (54.2%) had received additional neoadjuvant radiotherapy (NRT). NRT + surgery was associated with improved CSS comparing with surgery alone (HR, 0.58; 95%CI, 0.39 to 0.85; P = 0.005). In subgroup analysis, NRT was associated with improved CSS for patients aged 65–74 years (2-year CSS 56.6% versus 39.6%, P = 0.026). No significant differences of progonosis was observed for different treatment groups in 75–79 years patients (P = 0.972).
In this SEER-based study, the addition of neoadjuvant radiotherapy before surgery was associated with improved CSS for locally advanced ESCC patients aged 65 to 74 years.
KeywordsEsophageal squamous cell carcinoma Aged 65 and older Surgery Radiotherapy Survival
Conception and design: Shan Huang.
Development of methodology: Shan Huang, Yuxing Li.
Acquisition of data: Hongbing Ma, Shuyu Zheng, Yue Ke.
Analysis and interpretation of data: Wenyu Wang, Fang Li.
Writing, review and/or revision of the manuscript: Shan Huang, Wenyu Wang.
Study supervision: Shan Huang.
All authors have revised the manuscript and approved the final version to be published.
This work was supported by the Natural Science Foundation of Shaanxi Province [grant number 2017JM8099] and the Key Project of the Second Affiliated Hospital, Xi’an Jiaotong University [grant number YJ(ZD)201705].
Compliance with Ethical Standards
The Ethics Committee of the Health Science Center of Xi’an Jiaotong University approved the study.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 3.Howlader N, Noone A, Krapcho M. SEER cancer statistics review, 1975–2013. December 17, 2014. National Cancer Institute. 2017.Google Scholar
- 5.Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36: 2796–2803.CrossRefGoogle Scholar
- 6.Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014; 32: 2416–2422.CrossRefGoogle Scholar
- 8.van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074–2084.CrossRefGoogle Scholar
- 10.Greene FL, Page DL, Fleming ID (eds): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002.Google Scholar
- 11.National Cancer Institute. Appendix C: Site Specific Surgery Codes. https://seer.cancer.gov/manuals/2018/AppendixC/Surgery_Codes_Esophagus_2018.pdf.
- 12.Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 1991; 173: 123–130.PubMedGoogle Scholar
- 16.Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials G. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681–692.CrossRefGoogle Scholar